Bailard’s Calithera Biosciences, Inc CALA Stock Holding History

Bailard’s Portfolio CALA Stock Details CALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,114	Closed	-$49K	–	842
2022 Q1	$49K	Buy	+6,114	New	+$62.5K	﹤0.01%	712

Other funds holding CALA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bailard's CALA Position: Q2 2022 in Review

Bailard sold out of Calithera Biosciences, Inc (CALA) in Q2 2022, closing a stake of 6,114 shares — an estimated $49K sold.

Bailard first reported a position in CALA in Q1 2022 and held it in 1 quarter. The position peaked at $49K in Q1 2022. 28 funds tracked by Wall St. Rank hold CALA as of Q2 2022.

Bailard reported no remaining Calithera Biosciences, Inc position as of Q2 2022 after selling out during the quarter.
Bailard sold 6,114 Calithera Biosciences, Inc shares in Q2 2022, an estimated $49K.
Bailard first reported a position in Calithera Biosciences, Inc in Q1 2022 and held it in 1 quarter.
Bailard's Calithera Biosciences, Inc position peaked at $49K in Q1 2022.
28 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2022.

Based on Bailard's 13F filing for Q2 2022, filed 27 Jul 2022.